GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » Cyclically Adjusted Book per Share

Spyre Therapeutics (Spyre Therapeutics) Cyclically Adjusted Book per Share : $49.96 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Spyre Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Spyre Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $-0.025. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $49.96 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-04-29), Spyre Therapeutics's current stock price is $35.2375. Spyre Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $49.96. Spyre Therapeutics's Cyclically Adjusted PB Ratio of today is 0.71.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Spyre Therapeutics was 0.91. The lowest was 0.43. And the median was 0.60.


Spyre Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Spyre Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spyre Therapeutics Cyclically Adjusted Book per Share Chart

Spyre Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 49.96

Spyre Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 49.96

Competitive Comparison of Spyre Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Spyre Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Cyclically Adjusted PB Ratio falls into.



Spyre Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spyre Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.025/129.4194*129.4194
=-0.025

Current CPI (Dec. 2023) = 129.4194.

Spyre Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -42.026 99.070 -54.901
201503 -51.762 99.621 -67.245
201506 -56.454 100.684 -72.566
201509 -40.812 100.392 -52.613
201512 -48.573 99.792 -62.994
201603 -58.203 100.470 -74.973
201606 137.797 101.688 175.376
201609 126.944 101.861 161.289
201612 117.205 101.863 148.912
201703 106.270 102.862 133.707
201706 95.130 103.349 119.127
201709 84.242 104.136 104.696
201712 75.489 104.011 93.930
201803 65.319 105.290 80.289
201806 83.812 106.317 102.024
201809 72.043 106.507 87.542
201812 69.830 105.998 85.260
201903 100.815 107.251 121.654
201906 86.327 108.070 103.382
201909 68.971 108.329 82.399
201912 51.643 108.420 61.645
202003 36.714 108.902 43.631
202006 85.347 108.767 101.552
202009 76.230 109.815 89.839
202012 72.891 109.897 85.840
202103 63.115 111.754 73.092
202106 60.694 114.631 68.524
202109 51.759 115.734 57.879
202112 42.519 117.630 46.781
202203 31.190 121.301 33.277
202206 34.393 125.017 35.604
202209 27.456 125.227 28.375
202212 19.244 125.222 19.889
202303 12.865 127.348 13.074
202306 -64.001 128.729 -64.344
202309 -60.613 129.860 -60.408
202312 -0.025 129.419 -0.025

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Spyre Therapeutics  (NAS:SYRE) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Spyre Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=35.2375/49.96
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Spyre Therapeutics was 0.91. The lowest was 0.43. And the median was 0.60.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Spyre Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Spyre Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Spyre Therapeutics (Spyre Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Building 23,, Suite 105, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Executives
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Heidy King-jones officer: See Remarks C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Fairmount Healthcare Co-invest L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Cameron Turtle officer: Chief Operating Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Michael Thomas Henderson director 421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p. director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p. director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jeff Marc Goldberg director, officer: President and CEO C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142
Linda L Neuman officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
James Paul Kastenmayer officer: Interim CEO & General Counsel ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879
Hanley Jr. Michael Conick officer: Chief Commercial Officer C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746